Additional details on the meeting can be found at the WORLD Symposium website. About Spur Therapeutics Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing ...

HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February ...

a potential first-in-class gene therapy candidate for adrenomyeloneuropathy and a preclinical gene therapy candidate for Parkinson’s disease, as well as a research strategy to move gene therapy ...

Posters and publications are all found on ... on to studies in humans – and then comparing the results. Parkinson’s disease affects [mostly] dopaminergic neurons, resulting in a loss of ...

it is not often on the public’s radar like other disorders such as Parkinson’s Disease. Stephanie wants to see that changed, so she takes every opportunity she can to share her story to increase ...

STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases af ...

Schuyler Colfax, a former VP from Indiana, met his demise while on the lecture circuit in Minnesota during a cold stretch in ...

and Parkinson’s disease (PD), today announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The event will be held from October ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?